Who is CSL?
CSL is a global biotechnology company that develops, manufactures, and distributes biological medicines, including plasma-derived therapies, recombinant therapeutics, and vaccines, for clinical use in hematology, immunology, and related therapeutic areas.
- Plasma-derived therapies, including immunoglobulins, albumin, and coagulation factor products
- Recombinant and biologic therapeutics for rare and chronic conditions
- Vaccine research, development, and manufacturing, including influenza vaccines
- Large-scale biologics manufacturing supported by plasma collection and fractionation operations
- Research and development across hematology, immunology, and cardiovascular medicine
Show more
More About CSL
CSL operates in the biopharmaceutical segment of the health care sector, where biologic products are manufactured through complex, regulated processes. Its offerings are positioned for use in hospitals, specialty clinics, and public and private health systems, where clinicians rely on consistent supply, validated potency, and established safety profiles. Plasma-derived products depend on an integrated network of plasma collection, fractionation, purification, and quality control, and recombinant products rely on cell culture and bioprocess engineering. These production models require strict adherence to good manufacturing practice and to regulatory oversight from agencies such as national medicines regulators.
The company's products address conditions in which replacement or modulation of specific proteins is medically necessary. Immunoglobulin therapies support patients with primary immunodeficiency and certain autoimmune disorders. Albumin is used in critical care and surgical settings to manage fluid balance. Coagulation factor products treat bleeding disorders such as hemophilia. Vaccine activities, including seasonal influenza programs, relate to public health preparedness and to the supply chain resilience that national immunization programs require.
From a technical standpoint, the business spans upstream plasma sourcing, downstream purification and formulation, cold-chain logistics, and clinical development. Biopharmaceutical manufacturers in this category are often compared with other large plasma and biologics producers, since the scale, capital intensity, and regulatory requirements are similar. The business significance of these capabilities lies in sustained supply continuity, quality assurance across complex biological processes, and long-term clinical relevance in therapeutic areas with limited alternatives.
In the Decision Insights directory, the organization is positioned within current biotechnology and life sciences solution areas, reflecting its active focus on biologic therapies, vaccines, and manufacturing capability. The description above reflects established, publicly documented activities and is limited to general categories rather than specific product claims.
Our description of CSL. Updated October 2026.
